Cirugía torácica

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Comparison of Treatment Options for Achalasia

   Rochester, Minn.

   In this study we will review medical records and questionnaire results of patients that underwent PerOral Endoscopic Myotomy (POEM) + Partial Fundoplication (PF) and POEM and Laparoscopic Modified Heller Myotomy + PF for achalasia and access treatment outcomes by reviewing complications such as: delayed bleeding, pneumoperitoneum, pneumothorax, mucosal flap perforation, pneumomediastinum, cervical emphysema and displacement of transparent cap.

2. A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation

   Jacksonville, Fla.

   The purpose of this study is to evaluate L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with Bronchiolitis Obliterans Syndrome (BOS) following double-lung transplant. Patients will receive either L-CsA (5 mg) via the PARI Investigational eFlow® Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48 weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA following completion of BOSTON-2.

3. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary purpose of this study is to find out what effects (good or bad) the drugs auranofin and sirolimus have on patients with lung cancer; to find out if auranofin and sirolimus can stop or slow the growth of the lung cancer; to learn more about how auranafin and sirolimus work against lung cancer by testing blood and tissue samples.

4. A Study to Collect Medical and Personal Histories, Blood and/or Tumor Tissue Samples from Patients Who are Long-term Survivors of Lung Cancer

   Rochester, Minn.

   The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer.

5. ALEX Study: A Randomized, Phase III Study Comparing Alectinib with Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

   Scottsdale/Phoenix, Ariz.

   This randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with critozinib treatment in patients with treatment-naive ALK-positive advanced NSCLC. Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive treatment until disease progression, unacceptable toxicity, consent withdrawal or death occurs. The study is expected to last approximately 42 months.

6. A Study to Explore the Mechanisms that Separate Responders Versus Non-responders to Treatment such as Immunotherapy, Target Therapy and Chemotherapy in Lung Cancer Patients

   Jacksonville, Fla.

   The purpose of this study is to explore the underlying mechanisms that distinguishes responder versus non-responders to treatment such as immunotherapy, target therapy and chemotherapy in lung cancer and mechanisms of resistance. The information generated from this study will likely help to design the optimal strategies to improve clinical outcomes in lung cancers.

7. The Role of IL-33 Staining as a Biomarker and Immunotherapeutic Target

   Rochester, Minn.

   We are evaluating interleukin-33 and innate lymphoid cells in non-small cell lung cancer to further explain underlying mechanisms and assess their potential as prognostic biomarkers and targets in treatment.

8. A Study to Develop a Decision Aid for Patients Having Lung Screening

   Rochester, Minn.

   The purpose of this study is to collect data and then design a decision aid for patients who are having a lung screening.

9. Achalasia Patient Reported Outcomes

   Rochester, Minn.

   Patients that are either scheduled to undergo or have undergone an achalasia procedure at the Mayo Clinic Rochester are asked to participate. The purpose of this study is to gather information and determine if one of these procedures is superior to the other.

10. A Study of Response Rate and Survival from Combined Chemotherapy, Surgery and Radiation Therapy for Patients with Malignant Mesothelioma

    Rochester, Minn.

    The purpose of this study is to follow patients with malignant mesothelioma of the lung after they have had combined chemotherapy, surgery, and intensity modified radiation therapy and determine response rates and overall survival.